Mitoxantrone dihydrochloride (Synonyms: Mitozantrone dihydrochloride; NSC 301739 dihydrochloride)

Name: Mitoxantrone dihydrochloride
Brand: MedChemExpress
SKU: HY-13502A
Rating: 5.0 (46 reviews)

Cat. No.: HY-13502A Purity: 98.98%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity. Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively.

For research use only. We do not sell to patients.

CAS No. : 70476-82-3

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 46 publication(s) in Google Scholar

Other Forms of Mitoxantrone dihydrochloride:

Mitoxantrone In-stock
Mitoxantrone-d₈ dihydrochloride Get quote
Mitoxantrone-d₈ hydrochloride Get quote
Mitoxantrone diacetate Get quote
Mitoxantrone dihydrochloride (Standard) Get quote

46 Publications Citing Use of MCE Mitoxantrone dihydrochloride

Cell Proliferation/Viability Assay

Apoptosis Analysis

: Mitoxantrone dihydrochloride purchased from MedChemExpress. Usage Cited in: Exp Mol Med. 2025 Nov;57(11):2559-2573. [Abstract]; The USP11 inhibitor Mitoxantrone (5-20 μM; 24 h) was treated to A549 (western blotting for EGFR) cells. The EGFR protein levels were assessed by western blotting using an anti-EGFR antibody.

: Mitoxantrone dihydrochloride purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Aug 5;44(1):228. [Abstract]; U87-MG and U251 cells with stable CSRP2 overexpression (CSRP2) were treated with or without 0.5 µM Mitoxantrone (MTO) for indicated time periods and the cell proliferation was analyzed. Cells transfected with control vector (NC) were used as a negative control. Two-way ANOVA with Sidak’s post hoc test, n = 6 per group for U87-MG and U251.

: Mitoxantrone dihydrochloride purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Aug 5;44(1):228. [Abstract]; U87-MG and U251 cells with stable CSRP2 overexpression were treated with 0.5 µM Mitoxantrone (MTO) for 48 h and cell apoptosis was measured by flow cytometry

: Mitoxantrone dihydrochloride purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Jun;26(6):917-931. [Abstract]; HeLa cells were pre-treated with DMSO or Mitoxantrone (10 μM, 1 h) followed by Tg treatment (1 μM, 3 h).

: Mitoxantrone dihydrochloride purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Jun;26(6):917-931. [Abstract]; HeLa cells were pre-treated with DMSO or Mitoxantrone (10 μM, 1 h) followed by Tg treatment (1 μM, 3 h).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

View All Isoforms

Topoisomerase Topo I Topo II DNA gyrase

View All PKC Isoform Specific Products:

View All Isoforms

PKC PKCα PKCβ PKCγ PKCδ PKCε PKCη PKCζ PKCθ PKCμ PKC-ι ℩ PKCι

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms

Human Endogenous Metabolite Microbial Metabolite

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity^[1]^[2]^[3]^[4]. Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively^[5].

IC₅₀ & Target^[1]^[2]

PKC

8.5 μM (IC₅₀)

Topoisomerase II

Cellular Effect

Cell Line	Type	Value	Description	References
HL-60	IC₅₀	7.2 nM Compound: NVT	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 28333459]
HL60/MX2	IC₅₀	350.7 nM Compound: NVT	Antiproliferative activity against human HL60/MX2 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60/MX2 cells after 72 hrs by MTT assay	[PMID: 28333459]
LoVo	IC₅₀	0.1 μM Compound: Mitoxantrone	Cytotoxicity against human LoVo cells under oxic condition assessed as growth inhibition after 74 hrs by sulforhodamine B assay Cytotoxicity against human LoVo cells under oxic condition assessed as growth inhibition after 74 hrs by sulforhodamine B assay	[PMID: 22011244]
LoVo	IC₅₀	0.9 μM Compound: Mitoxantrone	Cytotoxicity against human LoVo cells under hypoxic condition assessed as growth inhibition after 74 hrs by sulforhodamine B assay Cytotoxicity against human LoVo cells under hypoxic condition assessed as growth inhibition after 74 hrs by sulforhodamine B assay	[PMID: 22011244]
MCF7	IC₅₀	0.1 μM Compound: Mitoxantrone	Cytotoxicity against doxorubicin-sensitive human MCF7 cells under oxic condition assessed as growth inhibition after 74 hrs by sulforhodamine B assay Cytotoxicity against doxorubicin-sensitive human MCF7 cells under oxic condition assessed as growth inhibition after 74 hrs by sulforhodamine B assay	[PMID: 22011244]
MCF7	IC₅₀	1 μM Compound: Mitoxantrone	Cytotoxicity against doxorubicin-sensitive human MCF7 cells under hypoxic condition assessed as growth inhibition after 74 hrs by sulforhodamine B assay Cytotoxicity against doxorubicin-sensitive human MCF7 cells under hypoxic condition assessed as growth inhibition after 74 hrs by sulforhodamine B assay	[PMID: 22011244]
MCF7	IC₅₀	4.7 μM Compound: Mitoxantrone	Cytotoxicity against doxorubicin-resistant human MCF7 cells under oxic condition assessed as growth inhibition after 74 hrs by sulforhodamine B assay Cytotoxicity against doxorubicin-resistant human MCF7 cells under oxic condition assessed as growth inhibition after 74 hrs by sulforhodamine B assay	[PMID: 22011244]
MCF7	IC₅₀	> 10 μM Compound: Mitoxantrone	Cytotoxicity against doxorubicin-resistant human MCF7 cells under hypoxic condition assessed as growth inhibition after 74 hrs by sulforhodamine B assay Cytotoxicity against doxorubicin-resistant human MCF7 cells under hypoxic condition assessed as growth inhibition after 74 hrs by sulforhodamine B assay	[PMID: 22011244]

In Vitro

Mitoxantrone dihydrochloride inhibits PKC in a competitive manner with respect to histone H1, and its K_i value is 6.3 μM and in a non-competitive manner with respect to phosphatidylserine and ATP^[1].
Mitoxantrone dihydrochloride (0.5 μg/mL, 48 h) induces a decrease in B-CLL cells. Mitoxantrone dihydrochloride induces DNA fragmentation and the proteolytic cleavage of poly(ADP-ribose) polymerase (PARP), demonstrating that the cytotoxic effect of Mitoxantrone dihydrochloride is due to induction of apoptosis^[2].
Mitoxantrone dihydrochloride shows cytotoxicity to human breast carcinoma cell lines MDA-MB-231 and MCF-7 with IC₅₀ values of 18 and 196 nM, respectively^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Mitoxantrone dihydrochloride (IP, 0-3.2 mg/kg/day) produces a statistically significant number of 60-day survivors at 1.6 mg/kg in mice with IP implanted L1210 leukemia^[4].
Mitoxantrone dihydrochloride (IV, 0-3.2 mg/kg/day) shows effective antitumor activities and produces a 60% ILS (increase in lifespan) at 3.2 mg/kg in SC implanted Lewis lung carcinoma^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

517.40

Formula

C₂₂H₃₀Cl₂N₄O₆

CAS No.

70476-82-3

Appearance

Solid

Color

Dark blue to black

SMILES

O=C1C2=C(C(NCCNCCO)=CC=C2NCCNCCO)C(C3=C(O)C=CC(O)=C13)=O.[H]Cl.[H]Cl

Structure Classification

Initial Source

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

H₂O : 100 mg/mL (193.27 mM; Need ultrasonic)

DMSO : 31.25 mg/mL (60.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9327 mL	9.6637 mL	19.3274 mL
5 mM	0.3865 mL	1.9327 mL	3.8655 mL
10 mM	0.1933 mL	0.9664 mL	1.9327 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture and light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 2 mg/mL (3.87 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 98.98%

Select Batch:

Data Sheet (283 KB) SDS (418 KB)

COA (254 KB) HNMR (129 KB) LCMS (99 KB)

Handling Instructions (2659 KB)

References

[1]. Takeuchi N, et al. Inhibitory effect of mitoxantrone on activity of protein kinase C and growth of HL60 cells. J Biochem. 1992 Dec;112(6):762-7. [Content Brief]

[2]. Bellosillo B, et al. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6. [Content Brief]

[3]. Venza I, et al. Class II-specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma cells. Pigment Cell Melanoma Res. 2013 Mar;26(2):193-204. [Content Brief]

[4]. Fujimoto S, et al. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. Cancer Chemother Pharmacol. 1982;8(2):157-62. [Content Brief]

[5]. Sharon E Altmann, et al. Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone. Antiviral Res. 2012 Feb;93(2):305-308. [Content Brief]

Cell Assay ^[3]	The human breast carcinoma cell lines MDA-MB-231 and MCF-7 are seeded in standard 96-well plates. One day after seeding, the culture medium is changed and replaced by medium containing different concentration of Mitoxantrone (10^-5 to 5 μM) with or without DHA (30 μM) during 7 days. Viability of cells are measured as a whole by the tetrazolium salt assay^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[4]	Mice: Mitoxantrone is tested for antitumor activity against experimental tumors in mice and the results are compared with those of seven antitumor antibiotics. The drugs are given IP or IV, in general on days 1, 5, and 9 following tumor inoculation. Mitoxantrone is given IP at the optimal dose (1.6 mg/kg/day; as a free base)^[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Takeuchi N, et al. Inhibitory effect of mitoxantrone on activity of protein kinase C and growth of HL60 cells. J Biochem. 1992 Dec;112(6):762-7. [Content Brief] [2]. Bellosillo B, et al. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6. [Content Brief] [3]. Venza I, et al. Class II-specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma cells. Pigment Cell Melanoma Res. 2013 Mar;26(2):193-204. [Content Brief] [4]. Fujimoto S, et al. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. Cancer Chemother Pharmacol. 1982;8(2):157-62. [Content Brief] [5]. Sharon E Altmann, et al. Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone. Antiviral Res. 2012 Feb;93(2):305-308. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / H₂O	1 mM	1.9327 mL	9.6637 mL	19.3274 mL	48.3185 mL
	5 mM	0.3865 mL	1.9327 mL	3.8655 mL	9.6637 mL
	10 mM	0.1933 mL	0.9664 mL	1.9327 mL	4.8319 mL
	15 mM	0.1288 mL	0.6442 mL	1.2885 mL	3.2212 mL
	20 mM	0.0966 mL	0.4832 mL	0.9664 mL	2.4159 mL
	25 mM	0.0773 mL	0.3865 mL	0.7731 mL	1.9327 mL
	30 mM	0.0644 mL	0.3221 mL	0.6442 mL	1.6106 mL
	40 mM	0.0483 mL	0.2416 mL	0.4832 mL	1.2080 mL
	50 mM	0.0387 mL	0.1933 mL	0.3865 mL	0.9664 mL
	60 mM	0.0322 mL	0.1611 mL	0.3221 mL	0.8053 mL
H₂O	80 mM	0.0242 mL	0.1208 mL	0.2416 mL	0.6040 mL
H₂O	100 mM	0.0193 mL	0.0966 mL	0.1933 mL	0.4832 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Mitoxantrone dihydrochloride Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Mitoxantrone dihydrochloride (Synonyms: Mitozantrone dihydrochloride; NSC 301739 dihydrochloride)

Customer Review

Other Forms of Mitoxantrone dihydrochloride:

46 Publications Citing Use of MCE Mitoxantrone dihydrochloride

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

View All PKC Isoform Specific Products:

View All Endogenous Metabolite Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Mitoxantrone dihydrochloride Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Mitoxantrone dihydrochloride (Synonyms: Mitozantrone dihydrochloride; NSC 301739 dihydrochloride)

Customer Review

Other Forms of Mitoxantrone dihydrochloride:

Mitoxantrone dihydrochloride Related Antibodies

46 Publications Citing Use of MCE Mitoxantrone dihydrochloride

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

View All PKC Isoform Specific Products:

View All Endogenous Metabolite Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Mitoxantrone dihydrochloride Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Mitoxantrone dihydrochloride Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report